Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Palmieri, Gianna ^a   Bergamo, Paolo ^b   Luini, Alberto ^c   Ruvo, Menotti ^b   Gogliettino, Marta ^a   Langella, Emma ^b   Saviano, Michele ^b   Hegde, Ramanath N ^c   Sandomenico, Annamaria ^b   Rossi, Mose ^a  

^a INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^b CNR   (Italy)

^c TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLAMINO ACID RELEASING ENZYME; CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LINOLEIC ACID; PROTEASOME; PROTEIN P21; SMALL INTERFERING RNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; UBIQUITIN; ACYLAMINOACYL PEPTIDASE; ACYLAMINOACYL-PEPTIDASE; ARCHAEAL PROTEIN; CONJUGATED LINOLEIC ACID; OLIGOPEPTIDE; PEPTIDE HYDROLASE; PROTEINASE INHIBITOR;

ARTICLE; CANCER GROWTH; CELL ASSAY; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; GENETIC TRANSFECTION; ISOMER; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; APOPTOSIS; BINDING SITE; CELL STRAIN CACO 2; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG INTERACTION; ENZYME SPECIFICITY; GENETICS; HUMAN; ISOMERISM; METABOLISM; MUTATION; PROTEIN CONFORMATION; SULFOLOBUS SOLFATARICUS; TIME;

ARCHAEA;

ANIMALS; APOPTOSIS; ARCHAEAL PROTEINS; BINDING SITES; CACO-2 CELLS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOWN-REGULATION; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; ISOMERISM; LINOLEIC ACIDS, CONJUGATED; MODELS, MOLECULAR; MUTATION; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; PROTEOLYSIS; RNA, SMALL INTERFERING; SUBSTRATE SPECIFICITY; SULFOLOBUS SOLFATARICUS; TIME FACTORS; UBIQUITIN;

EID: 80053912078     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025888     Document Type: Article

References (49)

1. Ciechanover A, (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6: 79-87.
2. Schwartz AL, Ciechanover A, (2009) Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 49: 73-96.
3. Shah IM, Di Napoli M, (2007) The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases. Cardiovasc Hematol Disord Drug Targets 7: 250-273.
4. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC, (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639.
5. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, et al. (2000) Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 65: 221-236.
6. Drexler HCA, (1997) Activation of the cell death program by inhibition of proteasome function, Proc Natl Acad Sci USA 94: 855-860.
7. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T, (1994) The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78: 773-785.
8. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P, (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21: 30-36.
9. Vlahakis SR, Badley AD, (2006) Influence of proteasome inhibitors on apoptosis. Curr Opin Clin Nutr Metab Care 9: 42-47.
10. Orlowski RZ, Kuhn DJ, (2008) Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade. Clin Cancer Res 14: 1649-1657.
11. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, et al. (2006) The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 9: 263-273.
12. Serini S, Piccioni E, Merendino N, Calviello G, (2009) Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 14: 135-152.
13. Park Y, (2009) Conjugated linoleic acid (CLA): Good or bad trans fat? J Food Compos Anal 22S: S4-S12.
14. Hamel FG, (2009) Preliminary report: inhibition of cellular proteasome activity by free fatty acids. Metabolism 58: 1047-1049.
15. Shimizu K, Kiuchi Y, Ando K, Hayakawa M, Kikugawa K, (2004) Coordination of oxidized protein hydrolase and the proteasome in the clearance of cytotoxic denatured proteins. Biochem Biophys Res Commun 324: 140-146.
16. Scaloni A, Jones W, Pospischil M, Sassa S, Schneewind O, et al. (1992) Deficiency of acylpeptide hydrolase in small-cell lung carcinoma cell lines. J Lab Clin Med 120: 546-552.
17. Palmieri G, Langella E, Gogliettino M, Saviano M, Pocsfalvi G, et al. (2010) A novel class of protease targets of phosphatidylethanolamine-binding proteins (PEBP): a study of the acylpeptide hydrolase and the PEBP inhibitor from the archaeon Sulfolobus solfataricus. Mol Biosyst 6: 2498-2507.
18. Palmieri G, Catara G, Saviano M, Langella E, Gogliettino M, et al. (2009) First Archaeal PEPB-Serine Protease Inhibitor from Sulfolobus solfataricus with Noncanonical Amino Acid Sequence in the Reactive-Site Loop. J Proteome Res 8: 327-334.
19. Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, et al. (2008) Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem 283: 34250-34259.
20. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, et al. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834.
21. Ward CL, Omura S, Kopito RR, (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83: 121-127.
22. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, et al. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83: 129-135.
23. Busse A, Kraus M, Na IK, Rietz A, Scheibenbogen C, et al. (2008) Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 112: 659-670.
24. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
25. Suzuki Y, Nakabayashi Y, Takahashi R, (2001) Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 98: 8662-8667.
26. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647.
27. Wertz IE, Dixit VM, (2010) Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol 2010 Mar;2 (3): a003350 (Ed. Louis M. Staudt and Michael Karin).
28. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M, (2003) Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 115: 71-82.
29. Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, et al. (2009) Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 8: 762-770.
30. Wahle KWJ, Heys SD, Rotondo D, (2004) Conjugated linoleic acids: are they beneficial or detrimental to health? Progr Lipid Res 43: 553-587.
31. Reynolds CM, Roche HM, (2010) Conjugated linoleic acid and inflammatory cell signalling. Prostaglandins Leukot Essent Fatty Acids 82: 199-204.
32. Bartlam M, Wang G, Yang H, Gao R, Zhao X, et al. (2004) Crystal structure of an acylpeptide hydrolase/esterase from Aeropyrum pernix K1. Structure 12: 1481-1488.
33. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1662.
34. Sacchinettini JC, Scapin G, Gopaul D, Gordon JI, (1992) Refinement of the structure of Escherichia coli-derived rat intestinal fatty acid binding protein with bound oleate to 1.75-A resolution. Correlation with the structures of the apoprotein and the protein with bound palmitate. J Biol Chem 267: 23534-45.
35. Hamilton JA, (2004) Fatty acid interactions with proteins: what X-ray crystal and NMR solution structures tell us. Progr Lipid Res 43: 177-99.
36. Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P, (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21: 30-36.
37. Saric T, Graef CI, Goldberg AL, (2004) Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 279: 46723-46732.
38. Ichinose Y, Genka K, Koike T, Kato H, Watanabe Y, et al. (2003) Randomized double-blind placebo controlled trial of bestatin in patients with resected stage I squamous-cell carcinoma. J Natl Cancer Inst 95: 605-610.
39. Perrier J, Durand A, Giardina T, Puigserver A, (2005) Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. Biochimie 87: 673-685.
40. Arnesen T, Van Damme P, Polevoda B, Helsens K, Evjenth R, et al. (2009) Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad Sci U S A 106: 8157-8162.
41. Goetze S, Qeli E, Mosimann C, Staes A, Gerrits B, et al. (2009) Identification and functional characterization of N-terminally acetylated proteins in Drosophila melanogaster. PLoS Biol 7: e1000236.
42. Boissel JP, Kasper TJ, Bunn HF, (1988) Cotranslational amino-terminal processing of cytosolic proteins. Cell-free expression of site-directed mutants of human hemoglobin. J Biol Chem 263: 8443-8449.
43. Kouzarides T, (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176-1179.
44. Shimizu K, Fujino T, Ando K, Hayakawa M, Yasuda H, et al. (2003) Overexpression of oxidized protein hydrolase protect COS-7 cells from oxidative stress-induced inhibition of cell growth and survival. Biochem Biophys Res Commun 304: 766-771.
45. Ben Saadon R, Fajerman I, Ziv T, Hellman U, Schwartz AL, et al. (2004) The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system. Direct evidence for ubiquitination at the N-terminal residue. J Biol Chem 279: 41414-41421.
46. Hwang CS, Shemorry A, Varshavsky A, (2010) N-terminal acetylation of cellular proteins creates specific degradation signals. Science 327: 973-977.
47. Fields GB, Noble RL, (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35: 161-214.
48. Decker T, Lohmann-Matthes ML, (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115: 61-69.
49. Koradi R, Billeter M, Wüthrich K, (1996) MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14: 51-5, 29-32.